Validation of uPath HER2 dual-colour dual in-situ hybridisation image analysis tool for HER2/neu testing in breast cancer
{{output}}
Aims: HER2/neu gene is amplified in 15%-20% of invasive breast cancers (IBCs), serving as critical prognostic and predictive marker. HER2-targeted therapies have improved outcomes for HER2-positive patients, highlighting the impo... ...
